The contributions of risk factor trends to cardiometabolic mortality decline in 26 industrialized countries

International Journal of Epidemiology

Volumn 42, Issue 3, 2013, Pages 838-848

  Cesare, Mariachiara Di ^a   Bennett, James ^a   Best, Nicky ^a   Ezzati, Majid ^a   Stevens, Gretchen ^b   Danaei, Goodarz ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Blood pressure; Cardiovascular disease; Cholesterol; Diabetes; Obesity; Smoking

Indexed keywords

CHOLESTEROL;

BODY MASS; CARDIOVASCULAR DISEASE; DIABETES; INDUSTRIALIZATION; MORTALITY; OBESITY; RISK FACTOR; SERUM; SMOKING;

ADULT; AGED; ARGENTINA; ARTICLE; AUSTRALIA; AUSTRIA; BELGIUM; BODY MASS; CANADA; CARDIOMETABOLIC RISK; CARDIOVASCULAR MORTALITY; CHILE; CHOLESTEROL BLOOD LEVEL; DENMARK; FEMALE; FINLAND; FRANCE; GERMANY; GREECE; GROSS NATIONAL PRODUCT; HUMAN; INDUSTRIALIZATION; IRELAND; ISRAEL; ITALY; JAPAN; JAPANESE; LUXEMBOURG; MAJOR CLINICAL STUDY; MALE; MEXICO; NETHERLANDS; NEW ZEALAND; NORWAY; PORTUGAL; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; SMOKING; SPAIN; SWEDEN; SWITZERLAND; SYSTOLIC BLOOD PRESSURE; UNITED KINGDOM; UNITED STATES;

BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CHOLESTEROL; DIABETES; OBESITY; SMOKING;

ADULT; AGED; BLOOD PRESSURE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CHOLESTEROL; DEVELOPED COUNTRIES; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; MORTALITY; OBESITY; RISK FACTORS; SMOKING;

AUSTRALIA; CANADA; FINLAND; FRANCE; MEXICO [NORTH AMERICA]; NETHERLANDS; NEW ZEALAND; SWITZERLAND; UNITED STATES;

EID: 84881585103     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyt063     Document Type: Article

References (50)

1. Uemura K, Pisa Z. Trends in cardiovascular disease mortality in industrialized countries since 1950. World Health Stat Q 1988;41:155-78.
2. Uemura K, Pisa Z. Recent trends in cardiovascular disease mortality in 27 industrialized countries. World Health Stat Q 1985;38:142-62.
3. Dobson AJ, Evans A, Ferrario M et al. Changes in estimated coronary risk in the 1980s: data from 38 populations in the WHO MONICA Project. Ann Med 1998;30: 199-205.
4. Levi F, Lucchini F, Negri E, La Vecchia C. Trends in mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world. Heart 2002;88: 119-24.
5. Preston SH. Mortality Patterns in National Populations: With Special Reference to Recorded Causes of Death. New York, London: Academic Press, 1976.
6. Ezzati M, Riboli E. Can noncommunicable diseases be prevented? Lessons from studies of populations and individuals. Science 2012;337:1482-87.
7. Vartiainen E, Laatikainen T, Peltonen M et al. Thirty-fiveyear trends in cardiovascular risk factors in Finland. Int J Epidemiol 2010;39:504-18.
8. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Selected major risk factors and global and regional burden of disease. Lancet 2002;360:1347-60.
9. Hunink MGM, Goldman L, Tosteson ANA et al. The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment. JAMA 1997;277:535-42.
10. Unal B, Critchley JA, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation 2004;109: 1101-07.
11. Wijeysundera HC, Machado M, Farahati F et al. Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005. JAMA 2010;303:1841-47.
12. Ford ES, Ajani UA, Croft JB et al. Explaining the decrease in US deaths from coronary disease, 1980-2000. N Engl J Med 2007;356:2388-98.
13. WHO MONICA Project Principal Investigators. The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. J Clin Epidemiol 1988;41(2):105-14.
14. Kuulasmaa K, Tunstall-Pedoe H, Dobson A et al. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet 2000;355:675-87.
15. Danaei G, Finucane MM, Lu Y et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011;378:31-40.
16. Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2013;380: 2095-128.
17. Finucane MM, Stevens GA, Cowan MJ et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011; 377:557-67.
18. Farzadfar F, Finucane MM, Danaei G et al. National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 countryyears and 3.0 million participants. Lancet 2011;377: 578-86.
19. Danaei G, Finucane MM, Lin JK et al. National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 countryyears and 5.4 million participants. Lancet 2011;377: 568-77.
20. Prospective Studies Collaboration. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009;373: 1083-96.
21. Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2007;298: 2654-64.
22. de Galan BE, Perkovic V, Ninomiya T et al. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009;20: 883-92.
23. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-78.
24. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-69.
25. Ni Mhurchu C, Parag V, Nakamura M, Patel A, Rodgers A, Lam TH. Body mass index and risk of diabetes mellitus in the Asia-Pacific region. Asia Pac J Clin Nutr 2006;15:127-33.
26. Murray CJ, Dias RH, Kulkarni SC, Lozano R, Stevens GA, Ezzati M. Improving the comparability of diabetes mortality statistics in the U.S. and Mexico. Diabetes Care 2008; 31:451-58.
27. Preston SH, Glei DA, Wilmoth JR. A new method for estimating smoking-attributable mortality in highincome countries. Int J Epidemiol 2010;39:430-38.
28. Pope CA 3rd, Ezzati M, Dockery DW. Fine-particulate air pollution and life expectancy in the United States. N Engl J Med 2009;360:376-86.
29. Peto R, Lopez AD, Boreham J, Thun M, Heath C Jr. Mortality from tobacco in developed countries: indirect estimation from national vital statistics. Lancet 1992; 339:1268-78.
30. World Health Organization. The Global Burden of Disease: 2004 Update. Geneva, Switzerland: World Health Organization, 2008.
31. World Health Organization. Global Status Report on Noncommunicable Diseases 2010. Geneva, Switzerland: World Health Organization, 2011.
32. Mathers CD, Fat DM, Inoue M, Rao C, Lopez AD. Counting the dead and what they died from: an assessment of the global status of cause of death data. Bull World Health Organ 2005;83:171-77.
33. Mathers CD, Lopez AD, Murray CJ. The burden of disease and mortality by condition: data, methods, and results for 2001. In Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL (eds). Global Burden of Disease and Risk Factors. New York: Oxford University Press, 2006.
34. Rodriguez BL, Labarthe DR, Huang B, Lopez-Gomez J. Rise of blood pressure with age. New evidence of population differences. Hypertension 1994;24:779-85.
35. Elliott P, Stamler J, Nichols R et al. Intersalt revisited: further analyses of 24 hour sodium excretion and blood pressure within and across populations. Intersalt Cooperative Research Group. BMJ 1996;312:1249-53.
36. Singh GM, Danaei G, Pelizzari PM et al. The age associations of blood pressure, cholesterol, and glucose: analysis of health examination surveys from international populations. Circulation 2012;125:2204-11.
37. James SL, Gubbins P, Murray CJ, Gakidou E. Developing a comprehensive time series of GDP per capita for 210 countries from 1950 to 2015. Popul Health Metrics 2012;10:12.
38. Danaei G, Singh GM, Paciorek CJ et al. on behalf of the Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group. The global cardiovascular risk transition: associations of four metabolic risk factors with national income, urbanization, and Western diet in 1980 and 2008. Circulation 2013;127(14):1493-1502.
39. Nicolosi A, Casati S, Taioli E, Polli E. Death from cardiovascular disease in Italy, 1972-1981: decline in mortality rates and possible causes. Int J Epidemiol 1988;17: 766-72.
40. Stevens GA, Finucane MM, Paciorek CJ, Flaxman SR et al. Trends in mild, moderate, and severe stunting and underweight, and progress towards MDG 1 in 141 developing countries: a systematic analysis of population representative data. Lancet 2012;380:824-34.
41. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665.
42. Puska P, Nissinen A, Tuomilehto J et al. The communitybased strategy to prevent coronary heart disease: conclusions from the ten years of the North Karelia project. Ann Rev Public Health 1985;6:147-93.
43. Szpiro AA, Paciorek CJ, Sheppard L. Does more accurate exposure prediction necessarily improve health effect estimates. Epidemiology 2011;22:680-85.
44. Szpiro AA, Sheppard L, Lumley T. Efficient measurement error correction with spatially misaligned data. Biostatistics 2011;12:610-23.
45. Gryparis A, Paciorek CJ, Zeka A, Schwartz J, Coull BA. Measurement error caused by spatial misalignment in environmental epidemiology. Biostatistics 2009;10:258-74.
46. Carroll RJ, Ruppert D, Stefanski LA, Ciprian C. Measurement Error in Nonlinear Models: a Modern Perspective. 2nd edn. Boca Raton, FL: Chapman & Hall/CRC, 2006.
47. Oza S, Thun MJ, Henley SJ, Lopez AD, Ezzati M. How many deaths are attributable to smoking in the United States. Comparison of methods for estimating smokingattributable mortality when smoking prevalence changes. Prev Med 2011;52:428-33.
48. Rose G. Sick individuals and sick populations. Int J Epidemiol 2001;30:427-32.
49. Puska P, Vartiainen E, Tuomilehto J, Salomaa V, Nissinen A. Changes in premature deaths in Finland: successful long-term prevention of cardiovascular diseases. Bull World Health Organ 1998;76:419-25.
50. Jackson R, Beaglehole R. Trends in dietary fat and cigarette smoking and the decline in coronary heart disease in New Zealand. Int J Epidemiol 1987;16:377-82.